Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhotoCure ASAFRA:PHS +1.91%80 Cash-to-Debt is No Debt (1) as of Jun. 2026, which is 100% below its 10-year median of 5,019.68. GuruFocus rates FRA:PHS with a GF Score™ of 80/100 and a GF Value™ of €6.61 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 983 Drug Manufacturers companies, PhotoCure ASA ranks better than 79.86% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PhotoCure ASA's cash to debt ratio for the quarter that ended in Jun. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PhotoCure ASAcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for PhotoCure ASA's Cash-to-Debt or its related term are showing as below:
FRA:PHS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 4.38 Med: 5019.68 Max: No Debt
Current: 15.7
During the past 13 years, PhotoCure ASA's highest Cash to Debt Ratio was No Debt. The lowest was 4.38. And the median was 5019.68.
FRA:PHS's Cash-to-Debt is ranked better than 79.86% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs FRA:PHS: 15.70
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
PhotoCure ASA Cash-to-Debt Related Terms
PhotoCure ASA Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:PHS vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's Cash-to-Debt falls into.
PhotoCure ASA's Cash to Debt Ratio for the quarter that ended in Jun. 2026 is calculated as:
PhotoCure ASA had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
PhotoCure ASA (FRA:PHS) has a Cash-to-Debt of No Debt (1) as of Jun. 2026. This is 100% below median its historical median of 5,019.68. Over the past decade, PhotoCure ASA's Cash-to-Debt has ranged from 4.38 to 10,000.00. According to the industry distribution chart, PhotoCure ASA ranks #198 out of 983 companies in the Drug Manufacturers industry, placing it in the top 20.1%.
Is PhotoCure ASA's Cash-to-Debt too high?
PhotoCure ASA's current Cash-to-Debt of No Debt (1) is 100% below median its 10-year median of 5,019.68. Over the past 10 years, this metric has ranged from a low of 4.38 to a high of 10,000.00. Based on the distribution chart, PhotoCure ASA ranks #198 out of 983 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PhotoCure ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #198 out of 983 companies for Cash-to-Debt. This places PhotoCure ASA in the top 20% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.98. Historically, PhotoCure ASA's own Cash-to-Debt has ranged from 4.38 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current Cash-to-Debt is No Debt (1), which is 100% below median its own 10-year median of 5,019.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.61, compared to a current price of €4.80 — trading 27.5% below its estimated fair value. The current Cash-to-Debt is No Debt (1), which is 100% below median its 10-year median of 5,019.68. PhotoCure ASA's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Cash-to-Debt is No Debt (1) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €4.80 is trading 27.5% below its estimated GF Value™ of €6.61.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for FRA:PHS:
Cash-to-Debt: No Debt (1) (100% below median its 10-year median of 5,019.68)
GF Value™: €6.61 vs. price of €4.80 (27.5% below fair value)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
80GF Score
Get the complete analysis for FRA:PHS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
